US Patent

US8093423 — Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same

Method of Use · Assigned to GloboAsia LLC · Expires 2026-04-21 · 0y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of making and using pharmaceutical-grade ferric citrate for treating disorders with elevated serum phosphate levels.

USPTO Abstract

The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1577 Auryxia

Patent Metadata

Patent number
US8093423
Jurisdiction
US
Classification
Method of Use
Expires
2026-04-21
Drug substance claim
No
Drug product claim
No
Assignee
GloboAsia LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.